Ocular Therapeutix (OCUL) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BTIG Downgrades Ocular Therapeutix (OCUL) to Neutral
May 5, 2017 2:35 PM EDTBTIG downgraded Ocular Therapeutix (NASDAQ: OCUL) from Buy to Neutral. Analyst Dane Leone thinks there is risk of a delay in the current PDUFA date for Dextenza.
For an analyst ratings summary and ratings history on Ocular Therapeutix... More
